CLEC12A and B-cell chronic lymphocytic leukemia: We confirmed higher CLL-1 expression in the MNC population based on a metric of median fluorescence intensity (MFI) > 1.5-fold increased versus an FMO (fluorescence minus one) CLL-1 control with a CLL-1 isotype antibody (Fig. 3A and Supplementary Fig. 4B, C) in 39 of 46 samples.